1. In vivo Therapeutic Synergism of Anti–Epidermal Growth Factor Receptor and Anti-HER2 Monoclonal Antibodies against Pancreatic Carcinomas
   Christel Larbouret et al, 2007, Clinical Cancer Research CrossRef
2. Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies
   Tasuku Matsuoka, 2016, World Journal of Gastroenterology CrossRef
3. Lessons Learned in the Management of Advanced Pancreatic Cancer
   Eric Van Cutsem et al, 2007, Journal of Clinical Oncology CrossRef
4. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
   Malcolm J. Moore et al, 2007, Journal of Clinical Oncology CrossRef
5. Pancreatic Cancer Signaling Pathways, Genetic Alterations, and Tumor Microenvironment: The Barriers Affecting the Method of Treatment
   Darya Javadrashid et al, 2021, Biomedicines CrossRef
6. Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine?
   Christopher Montemagno et al, 2021, International Journal of Molecular Sciences CrossRef
7. A Phase I Trial of the Dual Farnesyltransferase and Geranylgeranyltransferase Inhibitor L-778,123 and Radiotherapy for Locally Advanced Pancreatic Cancer
   Neil E. Martin et al, 2004, Clinical Cancer Research CrossRef
8. Apoptosis-inducing effect of erlotinib is potentiated by 3,3′-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer
   Shadan Ali et al, 2008, Molecular Cancer Therapeutics CrossRef
9. The Prognostic and Predictive Role of Epidermal Growth Factor Receptor in Surgical Resected Pancreatic Cancer
   Meng Guo et al, 2016, International Journal of Molecular Sciences CrossRef
10. Icotinib plus gemcitabine for metastatic pancreatic cancer: A case report
    Jing Zhao et al, 2015, World Journal of Gastroenterology CrossRef
11. New targeted therapies in pancreatic cancer
    Andrada Seicean, 2015, World Journal of Gastroenterology CrossRef
12. A Novel Monoclonal Antibody Targets Mucin1 and Attenuates Growth in Pancreatic Cancer Model
    Guang Wu et al, 2018, International Journal of Molecular Sciences CrossRef
13. Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line
    Ying-Ying Lu et al, 2008, World Journal of Gastroenterology CrossRef
14. Biomarkers in Pancreatic Cancer as Analytic Targets for Nanomediated Imaging and Therapy
    Cristiana Maria Grapa et al, 2021, Materials CrossRef
15. Pancreatic Cancer Cell Radiation Survival and Prenyltransferase Inhibition: The Role of K-Ras
    Thomas B. Brunner et al, 2005, Cancer Research CrossRef
16. Pancreatic adenocarcinoma: molecular drivers and the role of targeted therapy
    Bayan Al-Share et al, 2021, Cancer and Metastasis Reviews CrossRef
17. Overexpression of Circular RNA circ_0013587 Reverses Erlotinib Resistance in Pancreatic Cancer Cells Through Regulating the miR-1227/E-Cadherin Pathway
    Huiting Xu et al, 2021, Frontiers in Oncology CrossRef
18. Analysis of liver metastasis after resection for pancreatic ductal adenocarcinoma
    Kwang Yeol Paik, 2012, World Journal of Gastrointestinal Oncology CrossRef
19. Degalactotigonin, a Steroidal Glycoside from Solanum nigrum, Induces Apoptosis and Cell Cycle Arrest via Inhibiting the EGFR Signaling Pathways in Pancreatic Cancer Cells
    Hoang Le Tuan Anh et al, 2018, BioMed Research International CrossRef